Tags

Type your tag names separated by a space and hit enter

Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections.
Am J Med. 1993 Mar 22; 94(3A):150S-154S.AJ

Abstract

Oral fleroxacin, 400 mg once a day, and oral amoxicillin/clavulanate potassium (AMX/CP), 400 mg/125 mg three times a day, administered for 4-21 days, were compared for efficacy and safety in the treatment of skin and soft tissue infections. A total of 113 patients were enrolled in a multicenter, randomized, double-blind trial; 57 were assigned to fleroxacin and 56 to AMX/CP. A total of 22 and 33 patients in the fleroxacin and AMX/CP groups, respectively, were evaluable for efficacy. The most common diagnoses were skin abscess (14; 62%) and wound infections (5; 23%) in the fleroxacin group and skin abscess (17; 52%) and skin ulcer (9; 27%) in the AMX/CP group. A total of 20 (91%) of the fleroxacin-treated patients and 29 (88%) of the AMX/CP-treated patients were bacteriologically cured (two fleroxacin- and one AMX/CP-treated patients developed super-infection). The eradication rate for Staphylococcus aureus was 100% (11 of 11) in the fleroxacin group and 89% (17 of 19) in the AMX/CP group; 18 (82%) of the fleroxacin group and 25 (76%) of the AMX/CP group were clinically cured. Adverse events were seen in 22% (12 of 54) of the fleroxacin group and 25% (13 of 53) of the AMX/CP group. None were serious. Bacteriologic and clinical cure rates and safety results for the two groups were similar. The small sample size precluded statistical analysis at the 95% confidence level.

Authors+Show Affiliations

Department of Surgery, Tulane University Medical Center, New Orleans, Louisiana 70112.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8452172

Citation

Smith, J W., and R L. Nichols. "Comparison of Oral Fleroxacin With Oral Amoxicillin/clavulanate for Treatment of Skin and Soft Tissue Infections." The American Journal of Medicine, vol. 94, no. 3A, 1993, 150S-154S.
Smith JW, Nichols RL. Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. Am J Med. 1993;94(3A):150S-154S.
Smith, J. W., & Nichols, R. L. (1993). Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. The American Journal of Medicine, 94(3A), 150S-154S.
Smith JW, Nichols RL. Comparison of Oral Fleroxacin With Oral Amoxicillin/clavulanate for Treatment of Skin and Soft Tissue Infections. Am J Med. 1993 Mar 22;94(3A):150S-154S. PubMed PMID: 8452172.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. AU - Smith,J W, AU - Nichols,R L, PY - 1993/3/22/pubmed PY - 1993/3/22/medline PY - 1993/3/22/entrez SP - 150S EP - 154S JF - The American journal of medicine JO - Am J Med VL - 94 IS - 3A N2 - Oral fleroxacin, 400 mg once a day, and oral amoxicillin/clavulanate potassium (AMX/CP), 400 mg/125 mg three times a day, administered for 4-21 days, were compared for efficacy and safety in the treatment of skin and soft tissue infections. A total of 113 patients were enrolled in a multicenter, randomized, double-blind trial; 57 were assigned to fleroxacin and 56 to AMX/CP. A total of 22 and 33 patients in the fleroxacin and AMX/CP groups, respectively, were evaluable for efficacy. The most common diagnoses were skin abscess (14; 62%) and wound infections (5; 23%) in the fleroxacin group and skin abscess (17; 52%) and skin ulcer (9; 27%) in the AMX/CP group. A total of 20 (91%) of the fleroxacin-treated patients and 29 (88%) of the AMX/CP-treated patients were bacteriologically cured (two fleroxacin- and one AMX/CP-treated patients developed super-infection). The eradication rate for Staphylococcus aureus was 100% (11 of 11) in the fleroxacin group and 89% (17 of 19) in the AMX/CP group; 18 (82%) of the fleroxacin group and 25 (76%) of the AMX/CP group were clinically cured. Adverse events were seen in 22% (12 of 54) of the fleroxacin group and 25% (13 of 53) of the AMX/CP group. None were serious. Bacteriologic and clinical cure rates and safety results for the two groups were similar. The small sample size precluded statistical analysis at the 95% confidence level. SN - 0002-9343 UR - https://www.unboundmedicine.com/medline/citation/8452172/Comparison_of_oral_fleroxacin_with_oral_amoxicillin/clavulanate_for_treatment_of_skin_and_soft_tissue_infections_ L2 - https://medlineplus.gov/bacterialinfections.html DB - PRIME DP - Unbound Medicine ER -